ITCC pediatric preclinical POC platform
ITCC-P4 project logo


Start Date
End Date
IMI2 - Call 7
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
7 370 000
EFPIA in kind
8 450 094
742 738
Total Cost
16 562 832


Today, 20% of childhood cancers remain incurable and cancer kills 6 000 young people in Europe every year, making it the leading cause of disease-related death in the under-19s. Moreover, two thirds of those who survive a cancer in childhood experience long-term side effects as a result of their treatment. The challenge for scientists seeking to develop new treatments is the lack of tools to study childhood cancers, which are quite different in nature to most cancers found in adults.

The ITCC-P4 project will develop a large-scale platform comprising 400 novel research tools based on cells and tissues from patients covering 10 common childhood cancers, including neuroblastoma, high grade glioma, and osteosarcoma. The tools will allow researchers to explore the biology of paediatric cancers, identify sub-groups of patients that might respond better to certain treatments, and carry out tests on potential drugs.

Ultimately, the platform should significantly add to our understanding of childhood cancers and speed up the development of new treatments.

Achievements & News

Participants Show participants on map

EFPIA companies
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Charles River Discovery Research Services Germany GMBH, Freiburg, Germany
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Pharmamar, S.A., Colmenar Viejo, Spain
Universities, research organisations, public bodies, non-profit groups
  • Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands
  • Alleanza Contro Il Cancro, Roma, Italy
  • Charite - Universitaetsmedizin Berlin, Berlin, Germany
  • Deutsches Krebsforschungszentrum Heidelberg, Heidelberg, Germany
  • Fundacio Sant Joan De Deu, Esplugues de Llobregat, Spain
  • Innovative Therapies For Children With Cancer Association, Villejuif, France
  • Institut Curie, Paris, France
  • Institut Gustave Roussy, Villejuif, France
  • Medizinische Universitaet Wien, Vienna, Austria
  • Prinses Maxima Centrum Voor Kinderoncologie BV, Utrecht, Netherlands
  • St. Anna Kinderkrebsforschung, Vienna, Austria
  • The Institute Of Cancer Research: Royal Cancer Hospital, London, United Kingdom
  • Universitat Zurich, Zürich, Switzerland
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Experimentelle Pharmakologie Und Onkologie Berlin-Buch GMBH, Berlin, Germany
  • Xentech SAS, Evry, France
Third parties
  • Fondazione Irccs Istituto Nazionale Dei Tumori, Milano, Italy
  • Gustave Roussy Transfert, Villejuif, France
  • Istituto Ortopedico Rizzoli, Bologna, Italy
  • Ospedale Pediatrico Bambino Gesu, Rome, Italy
Project leader
Louis Stancato
Eli Lilly and Company
Project co-leader
Hubert Caron